- Recent Funding
- Investors
- Imperial Innovations
Imperial Innovations portfolio
Imperial Innovations has 2 portfolio companies on record at Recent Funding.
About this page
Its most recent investment on record is Storm Therapeutics's $16.06M Series A round in June 2016, alongside Cambridge Innovation Capital, Touchstone Innovations, Pfizer Venture Investments and 1 other. By category, its portfolio leans toward Health and bio (2).
What Imperial Innovations invests in
- Health and bio · 2 · 100%
How Imperial Innovations invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series A | 1 100% | $16.06M |
Imperial Innovations portfolio companies
SStorm Therapeutics$16.06MSeries A · Jun 2016
AAkamis Biobacker
| Company | Round with Imperial Innovations | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $16.06M | $102.06M | Apr 16, 2026 Series B+ |
Health and bio |
backer | $60M | Dec 17, 2024 Series A |
Most frequent co-investors
MM Ventures1 shared round · last Jun 28, 2016
CCambridge Innovation Capital1 shared round · last Jun 28, 2016
PPfizer Venture Investments1 shared round · last Jun 28, 2016
- TTouchstone Innovations1 shared round · last Jun 28, 2016
Similar investors
IIzou Partners2 companies · 2 deals in 12 mo
- TThe Ljungstrom Family Office2 companies · 2 deals in 12 mo
OO'Shaughnessy Ventures3 companies · 1 deal in 12 mo
SSide Stage Ventures3 companies
AAble Partners4 companies · 1 deal in 12 mo
BBdc Thrive venture5 companies · 3 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 1 round on Recent Funding that name Imperial Innovations. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Imperial Innovations, which is a subset of its real portfolio. API: /api/v1/investors/imperial-innovations (get a free API key). More: the most active VC firms and new venture capital funds.